



Europass Curriculum Vitae

Informazioni personali

Nome / Cognome

Lucio Gnessi

Indirizzo

Dipartimento di Medicina Sperimentale, Sezione di Fisiopatologia Medica, Scienza dell'Alimentazione e Endocrinologia, Università di Roma "La Sapienza", Policlinico Umberto I, 00161, Rome, Italy

Telefono

Fax

E-mail

Nazionalità

Data di nascita

Sesso

Posizione

Professore Associato, Medicina Interna (Med 09)
Abilitazione Scientifica Nazionale - I Fascia - Settore 06N1, Scienze delle professioni sanitarie e delle tecnologie mediche applicate.

Esperienza professionale

Data 2015-

Occupazione o posizione

Medicina e chirurgia "F" in lingua inglese

Attività e responsabilità principali

Docente, supervisore dell'attività formativa

Nome e indirizzo datore di lavoro

Università di Roma "La Sapienza" Piazzale Aldo Moro, 5 - Rome 00185

Settore

Medicina

Data 2015-

Occupazione o posizione

Corso di Laurea triennale in Dietistica – Sede S. Camillo-Forlanini-

Attività e responsabilità principali

Docente, supervisore dell'attività formativa

Nome e indirizzo datore di lavoro

Università di Roma "La Sapienza" Piazzale Aldo Moro, 5 - Rome 00185

Settore

Medicina

Data 2013-

Occupazione o posizione

Comitato ordinatore – Scuola di Specializzazione, Scienza dell'Alimentazione

Attività e responsabilità principali

Docente, supervisore dell'attività formativa

Nome e indirizzo datore di lavoro

Università di Roma "La Sapienza" Piazzale Aldo Moro, 5 - Rome 00185

Settore

Medicina

Data

2013-ad oggi

Occupazione o posizione

Adjunct Professor

Attività e responsabilità principali	Clinical and research activities
Nome e indirizzo datore di lavoro	Temple University's College of Science and Technology, Philadelphia, USA
Settore	Department of Biology, Internal Medicine, Endocrinology
Data	2010-ad oggi
Occupazione o posizione	Responsabile UOS Centro per i Disturbi Alimentari e l'Obesità
Attività e responsabilità principali	Assistenza, ricerca e didattica
Nome e indirizzo datore di lavoro	Università "La Sapienza", Policlinico Umberto I, 00161, Roma, Italia
Settore	Medicina interna, Endocrinologia
Data	2010-2015
Occupazione o posizione	Direttore, Master I livello "Prevenzione e Assistenza a Sovrappeso Obesità e Disturbi dell'Alimentazione"
Attività e responsabilità principali	Didattica
Nome e indirizzo datore di lavoro	Università di Roma "La Sapienza"
Settore	Medicina interna, Endocrinologia
Data	2016- ad oggi
Occupazione o posizione	Direttore, Corso di alta Formazione "Obesità e Sovrappeso"
Attività e responsabilità principali	Didattica
Nome e indirizzo datore di lavoro	Università di Roma "La Sapienza"
Settore	Medicina interna, Endocrinologia
Data	2002-ad oggi
Occupazione o posizione	Professore Associato SSD MED/09 Medicina Interna
Attività e responsabilità principali	Assistenza, ricerca e didattica
Nome e indirizzo datore di lavoro	Università "La Sapienza", Policlinico Umberto I, 00161, Roma, Italia
Settore	Medicina interna, Endocrinologia, Medicina Sperimentale
Data	2000-ad oggi
Occupazione o posizione	Collegio dei docenti – Dottorato di Ricerca "Scienze Endocrinologiche, Metaboliche e Andrologiche (SEMA)"
Attività e responsabilità principali	Docente, supervisore dell'attività formativa e di ricerca
Nome e indirizzo datore di lavoro	Università di Roma "La Sapienza", Piazzale Aldo Moro, 5 - Rome 00185
Settore	Endocrinologia
Data	2000-ad oggi
Occupazione o posizione	Responsabile del Laboratorio di Biologia Cellulare e dello Sviluppo
Attività e responsabilità principali	Sviluppo testicolare, tessuto adiposo
Nome e indirizzo datore di lavoro	Università di Roma "La Sapienza" Piazzale Aldo Moro, 5 - Rome 00185
Settore	Medicina Sperimentale, Endocrinologia
Data	1990-ad oggi
Occupazione o posizione	Collegio dei docenti – Scuola di Specializzazione, Endocrinologia
Attività e responsabilità principali	Docente, supervisore dell'attività formativa
Nome e indirizzo datore di lavoro	Università di Roma "La Sapienza" Piazzale Aldo Moro, 5 - Rome 00185
Settore	Medicina

Istruzione e formazione

Data 1990
Titolo della qualifica Dottorato di Ricerca in Endocrinologia
Nome e tipo di organizzazione che ha rilasciato il titolo Università di Roma "La Sapienza"

Data 1983
Titolo della qualifica Specializzazione in Endocrinologia e Metabolismo
Nome e tipo di organizzazione che ha rilasciato il titolo Università di Roma "La Sapienza"

Data 1980
Titolo della qualifica Laurea in Medicina
Nome e tipo di organizzazione che ha rilasciato il titolo Università di Roma "La Sapienza"

Competenze personali

Endocrinologia clinica e sperimentale, obesità

Lingua madre Italiano

Autovalutazione
Livello europeo ()*
Lingua

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione		Spoken production			
C1	English	C2	English	B2	English	B2	English	C2	English

(*) [Common European Framework of Reference for Languages](http://europa.eu/rapid/press-release-2004-08-20.htm)

Informazioni aggiuntive

Includere qui ogni altra informazione considerata rilevante.

Allianza a Società Scientifiche

Società Italiana di Endocrinologia (SIE) – Membro
 Società Italiana dell'Obesità (SIO) – Membro
 Società Italiana di Andrologia e Medicina della Sessualità (SIAMS) – Membro
 European Society of Endocrinology (ESE) – Membro
 Società Italiana di Nutraceutica (SINut) - Membro

Scores (05.12.2016)

	ISI – Web of Science http://apps.webofknowledge.com/CitationReport.do?product=UA&search_mode=CitationReport&SID=Q2t9cXqCeKgyBkDL369&page=1&cr_pqid=1&viewType=summarily	Scopus https://www.scopus.com/cto2/main.uri?origin=resultslist&stateKey=CTOF_740325309	G-Scholar https://scholar.google.it/citations?user=PX7vgt4AAAAJ&hl=it&oi=ao
Total Impact Factor	621.77	621.77	621.77
Total Citations	2243	2254	3072
Average Citations per Product	20.77	22.3	23.09
Average Citations per Year	64.09	64.4	87.7
Hirsch (H) index	29	27	32

Lucio Gnessi is listed in the Italian top scientists (VIAcademy www.topitalianscientists.org)
 23.10.2017

Academic	H-index	Nation	Area	MacroArea	Italian_Institution	note
Lucio Gnessi	31	Italy	endocrinology - medicine	Clinical Sciences	Roma	Verified Google Scholar MyC Last Update: 23/10/2016

Allegati

1. Elenco delle pubblicazioni scientifiche più significative
2. Trials clinici

1. F. Fraioli, A. Fabbri, **L. Gnessi**, C. Moretti, C. Santoro, M. Felici. Subarachnoid salmon calcitonin injection induces analgesia in man.
Eur. J. Pharm. 78:381-382, 1982. **(3.370)**
2. C. Moretti, A. Fabbri, **L. Gnessi**, V. Bonifacio, F. Fraioli, A. Isidori. Piridoxine (B6) suppresses prolactin and increases GH rise induced by physical exercise.
New Engl. J. Med. 307:444, 1982. **(24.445)**
3. F. Fraioli, A. Fabbri, **L. Gnessi**, C. Moretti, C. Santoro, M. Felici. Subarachnoid calcitonin for intolerable pain.
Lancet ii: 831, 1982. **(15.940)**
4. A. Fabbri, F. Fraioli, **L. Gnessi**, C. Moretti, G. Bini, G. Cruccu, M. Manfredi. Is calcitonin an analgesic hormone?
Arch. Neurol. 40:64, 1983. **(3.517)**
5. C. Moretti, A. Fabbri, **L. Gnessi**, M. Cappa, A. Calzolari, F. Fraioli, A. Grossman, G.M. Besser. Naloxone inhibits exercise-induced release of PRL and GH in athletes.
Clin. Endocrinol. 18:135-138, 1983. **(2.279)**
6. C. Foresta, G. Scanelli, A. Fabbri, **L. Gnessi**, C. Moretti, F. Fraioli. Naloxone fails to increase LH levels in clomiphene treated males.
Horm. Met. Res. 16:140-142, 1984. **(0.674)**
7. C. De Carolis, G. De Sanctis, R. Perricone, C. Moretti, A. Fabbri, **L. Gnessi**, F. Fraioli, L. Fontana. Evidence for an inhibitory role of beta-endorphin and other opioids on human total T rosette formation.
Experientia 40:738-739, 1984. **(1.643)**
8. F. Fraioli, M. Cappa, A. Fabbri, **L. Gnessi**, C. Moretti, P. Borrelli, A. Isidori. Lack of endogenous opioid inhibitory tone on LH secretion in early puberty.
Clin. Endocrinol. 20:299, 1984. **(2.279)**
9. **L. Gnessi**, L. Ferraris, R. Ferretti, A. Fabbri, C. Moretti, V. Bonifacio, A. Isidori, F. Fraioli. In vitro bioassay of LH: some methodological aspects.
J. Endocrinol. Invest. 7 (suppl. 3):33-37, 1984. **(1.118)**
10. **L. Gnessi**, G. Camilloni, A. Fabbri, V. Politi, G. De Luca, G. Di Stazio, C. Moretti, F. Fraioli. In vitro interaction between calcitonin and calmodulin.
Biochem. Biophys. Res. Comm. 118:648-654, 1984. **(3.583)**
11. F. Fraioli, A. Fabbri, **L. Gnessi**, L. Silvestroni, C. Moretti, F. Redi, A. Isidori. Beta-endorphin, met-enkephalin and calcitonin in human semen. evidence for a possible role in human sperm motility.
Ann. New York Acad. Sci. 438:365-370, 1985. **(0.868)**
12. **L. Gnessi**, L. Silvestroni, A. Fabbri, C. Moretti, A.E. Panerai, V. Bonifacio, F. Fraioli. Salmon calcitonin inhibits human sperm motility in vitro.
Biochem. Biophys. Res. Comm. 125:199-204, 1984. **(3.583)**
13. A. Fabbri, **L. Gnessi**, R. Perricone, G. De Sanctis, C. Moretti, C. De Carolis, L. Fontana, F. Fraioli. Human semen inhibits total T rosette formation through an opiate mediated mechanism.
J. Clin. Endocrinol. Metab. 60:807-809, 1985. **(4.646)**
14. **L. Gnessi**, M. Ruff, F. Fraioli, C.B. Pert. Demonstration of receptor mediated chemotaxis by human spermatozoa: a novel quantitative bioassay.
Exp. Cell Res. 161:219-230, 1985. **(3.525)**
15. J. Patel, A. Fabbri, C.B. Pert, **L. Gnessi**, F. Fraioli, R. Mc Devitt. Calcitonin inhibits the phosphorylation of various proteins in rat brain synaptic membranes.
Biochem. Biophys. Res. Comm. 130:669-676, 1985. **(3.583)**
16. F. Fraioli, A. Fabbri, **L. Gnessi**, C. Moretti, V. Bonifacio, R. Ferretti, A. Isidori, M. Dufau. Naloxone increases bioactive LH in man: evidence for selective release of early LH pool.
J. Endocrinol. Invest. 8:513-518, 1985. **(1.118)**
17. **L. Gnessi**, A. Fabbri, L. Silvestroni, C. Moretti, F. Fraioli, C.B. Pert, A. Isidori. Evidence for the presence of specific receptors for N-formyl-chemotactic peptides on human spermatozoa.
J. Clin. Endocrinol. Metab. 63:841-846, 1986. **(4.646)**
18. L. Silvestroni, A. Menditto, G. Frajese, **L. Gnessi**. Identification of calcitonin receptors in human spermatozoa.
J. Clin. Endocrinol. Metab. 65:742-746, 1987. **(4.646)**
19. A. Fabbri, E.A. Jannini, **L. Gnessi**, S. Ulisse, C. Moretti, G. Frajese, A. Isidori. Evidence for low bioactive LH in male impotence: possible relationship with altered GnRH pulsatility.
J. Clin. Endocr. Metab. 67:867-875, 1988. **(4.646)**
20. S. Ulisse, **L. Gnessi**, A. Fabbri, E.A. Jannini, C. Moretti, V. Bonifacio, A. Di Luca Sidozzi, F. Fraioli, A. Isidori. Bombesin-like immunoreactivity in human seminal fluid.
Ann. New York Acad. Sci. 438:452-454, 1989. **(0.868)**
21. A. Fabbri, E.A. Jannini, **L. Gnessi**, C. Moretti, S. Ulisse, A. Franzese, R. Lazzari, F. Fraioli, G. Frajese, A. Isidori. Endorphins in male impotence. evidence for naltrexone stimulation of erectile activity in patient therapy.
Psychoneuroendocrinology 14:103-111, 1989. **(1.699)**
22. A. Fabbri, E.A. Jannini, **L. Gnessi**, S. Ulisse, C. Moretti, A. Isidori. Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites.
J. Steroid. Biochem. 32(1B):145-150, 1989. **(1.739)**

23. **L. Gnessi**, S. Ulisse, A. Fabbri, E.A. Jannini, V. Bonifacio, C. Moretti, G. Spera, A. Isidori. Isolation of a human seminal plasma peptide with bombesin-like activity.
Fertil. Steril. 51:1034-1039, 1989. **(2.788)**
24. **L. Gnessi**, A. Isidori, M. Bolotti, S. Altamura, S. Ulisse, E.A. Jannini, A. Fabbri, G. Spera. Identification of immunoreactive gastrin-releasing peptide related substances in adult Leydig cells.
Endocrinology 124:558-560, 1989. **(4.736)**
25. **L. Gnessi**, S. Altamura, M. Arizzi, C. Tei, C. La Torre, V. Bonifacio, F. Facchinetti, G. Spera. Gastrin-releasing peptide-like immunoreactivity in porcine follicular fluid and ovary.
Mol. and Cell. Endocrinol. 66:115-118, 1989. **(2.644)**
26. R. Perricone, C. Moretti, C. De Carolis, C. De Sanctis, **L. Gnessi**, A. Fabbri, F. Fraioli, A.E. Panerai, L. Fontana. Increased plasma beta-endorphin levels in hereditary angioedema.
Immunopharmacol. 18:89-96, 1989. **(1.761)**
27. C. Moretti, A. Fabbri, **L. Gnessi**, V. Bonifacio, M. Bolotti, M. Arizzi, Q. Nazzicone, G. Spera. Immunohistochemical localization of growth hormone releasing hormone in human gonads.
J. Endocrinol. Invest. 13:301-305, 1990. **(1.118)**
28. **L. Gnessi**, A. Emidi, D. Farini, S. Scarpa, A. Modesti, T. Ciampani, L. Silvestroni, G. Spera. Rat Leydig cells bind Platelet-Derived Growth Factor through specific receptors and produce Platelet-Derived Growth Factor-like molecules.
Endocrinology 130:2219-2224, 1992. **(4.736)**
29. **L. Gnessi**, A. Emidi, S. Scarpa, S. Palleschi, M. Ragano-Caracciolo, L. Silvestroni, A. Modesti, G. Spera. Platelet-derived growth factor effects on purified testicular peritubular myoid cells: binding, cytosolic Ca⁺⁺ increase, mytogenic activity, and extracellular matrix production enhancement.
Endocrinology 133:1880-1890, 1993. **(4.736)**
30. S. Adami, M.C. Baroni, M. Broggin, L. Carratelli, I. Caruso, **L. Gnessi**, M. Laurenzi, A. Lombardi, G. Norbiato, S. Ortolani, E. Ricerca, L. Romanini, S. Subrizi, J. Weinberg, A.J. Yates. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
Osteoporosis Int. 3 (suppl.3):S21-S27, 1993. **(2.906)**
31. **Gnessi L**, Emidi A, Jannini EA, Carosa E, Maroder M, Arizzi M, Ulisse S, Spera G. Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action.
J. Cell Biol. 131:1105-1121, 1995. **(12.149)**
32. S. Adami, M. Passeri, S. Ortolani, M. Broggin, L. Carratelli, I. Caruso, G. Gandolini, **L. Gnessi**, M. Laurenzi, A. Lombardi, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Bone 17:383-90, 1995. **(2.134)**
33. **Gnessi L**, Fabbri A, Spera G. Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment.
Endocr. Rev. 18:541-609, 1997. **(22.848)**
34. S. Ulisse, N. Rucci, D. Piersanti, E. Carosa, F.M. Graziano, A. Pavan, P. Ceddia, M. Arizzi, P. Muzi, L. Cironi, **L. Gnessi**, M. D'Armiento, E.A. Jannini. Regulation by thyroid hormone of the expression of basement membrane components in rat prepubertal Sertoli cells.
Endocrinology 139:741-747, 1998 **(4.736)**
35. **L. Gnessi**, S. Basciani, S. Mariani, M. Arizzi, G. Spera, C. Wang, C. Bondjers, L. Karlsson, C. Betsholtz. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice.
J. Cell. Biol. 149:1019-1025, 2000 **(13.955)**
36. S. Francavilla, P. D'Abrizio, N. Rucci, G. Silvano, G. Properzi, E. Straface, G. Cordeschi, S. Necozone, **L. Gnessi**, M. Arizzi, S. Ulisse. Fas and Fas ligand expression in fetal and adult human testis with normal or deranged spermatogenesis.
J. Clin. Endocrinol. Metab. 85:2692-2700, 2000 **(5.641)**
37. A. Aversa, S. Basciani, P. Visca, M. Arizzi, **L. Gnessi**, G. Frajese, A. Fabbri. Platelet-derived growth factor (PDGF) and PDGF-receptors in rat corpus cavernosum: changes in expression after transient *in vivo* hypoxia
J. Endocrinol. 170:395-402, 2001 **(2.395)**
38. S. Mariani, S. Basciani, M. Arizzi, G. Spera and **L. Gnessi**. PDGF and the testis.
Trends Endocrinol. Metab. 13:11-17, 2002 **(7.969)**
39. S. Basciani, S. Mariani, M. Arizzi, S. Ulisse, N. Rucci, E. A. Jannini, C. Della Rocca, A. Manicone, C. Carani, G. Spera, and **L. Gnessi**. Expression of PDGF-A, PDGF-B, PDGFR- α and PDGFR- β during human testicular development and disease.
J. Clin. Endocrinol. Metab. 87: 2310-2319, 2002 **(5.641)**
40. M. Caprio, E. Fabbri, G Ricci, S. Basciani, **L. Gnessi**, M. Arizzi, A.R. Carta, M.U. De Martino, A. M. Isidori, G.V. Frajese, A. Fabbri. Ontogenesis of leptin receptor in rat Leydig cells.
Biol. Reprod. 68: 1199-1207, 2003 **(3.508)**
41. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G and **Gnessi L**. Gynecomastia in men with chronic myeloid leukemia after imatinib.
The Lancet 361: 1954-1956, 2003 **(18.316)**
42. Spera G, Pili M, **Gnessi L**, Spera E, Mariani S. Medical therapy of sexual dysfunction.
J Endocrinol Invest. 26(3 Suppl):132-136, 2003. **(1.592)**

43. Basciani S, Mariani S, Arizzi M, Brama M, Ricci A, Betsholtz C, Bondjers C, Ricci G, Catizone A, Galdieri M, Spera G, **Gnessi L**. Expression of platelet-derived growth factor (PDGF) in the epididymis and analysis of the epididymal development in PDGF-A, PDGF-B, and PDGF receptor beta deficient mice. **Biol Reprod.** 2004;70(1):168-177. (3.508)
44. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G and **Gnessi L**. Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for *In Vitro* and *In Vivo* Activity. **Cancer Research**, 65: 1897-1903, 2005 (8.426)
45. Mammi C, Frajese GV, Vespasiani G, Mariani S, **Gnessi L**, Farini D, Fabbri A, Frajese G, Moretti C. PAC1-R null isoform expression in human prostate cancer tissue. **Prostate**, 66:514-521, 2006. (4.331)
46. Moretti C, Mammi C, Frajese GV, Mariani S, **Gnessi L**, Arizzi M, Wannenes F, Frajese G. PACAP and type I PACAP receptors in human prostate cancer tissue. *Ann N Y Acad Sci.* **1070:440-449**, 2006. (1.789)
47. **Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G and Gnessi L**. Expression and cellular localization of the FSH receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. *J Urol*, **175:2072-2077**, 2006 (3.297)
48. **Brama M, Gnessi L, Cherubini S, Cerulli N, Politi L, Spera G, Mariani S, Basciani S, d'Abusco AS, Scandurra R and Migliaccio S**. Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. *Mol and Cellular Endocrinol*, **264: 102-108**, 2007 (2.786)
49. **Brama M, Basciani S, Cherubini S, Mariani S, Migliaccio S, Arizzi M, Rosano G, Spera G and Gnessi L**. Osteoblast conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment. *Endocr Related Cancer*, **14: 61-72**, 2007, (4.905)
50. Basciani S, Vona R, Matarrese P, Ascione B, Mariani S, **Gnessi L**, Malorni W, and Straface E. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. **FEBS Letter**, 581: 5897-5903, 2007 (3.372)
51. Mariani S, Giona F, Basciani S, Brama M and **Gnessi L**. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. *The Lancet*, **372: 111-112**, 2008 (28.409)
52. Basciani S, De Luca G, Dolci S, Brama M, Arizzi M, Mariani S, Rosano G, Spera G and **Gnessi L**. Platelet-Derived Growth Factor Receptor β -Subtype Regulates Proliferation and Migration of Gonocytes. **Endocrinology**, 149: 6226-6235, 2008 (5.236)
53. **Mariani S, Tornaghi L, Sassone M, Basciani S, Buzzetti R, Gambacorti-Passerini C, Spera G and Gnessi L** Imatinib does not substantially modify the glycemic profile in diabetic and non-diabetic patients. **Leukemia Research** - January 2010 (Vol. 34, Issue 1, Pages e5-e7, DOI: 10.1016/j.leukres.2009.08.003 (2.923)
54. Basciani S, Mariani S, Spera G, and **Gnessi L** Role of Platelet-Derived Growth Factors (PDGFs) in the Testis. **Endocrine Reviews**, 12: 916-939, 2010 (24.444)
55. Mariani S, Basciani S, Fabbri A, Agati L, Ulisse S, Malorni W, Lubrano C, Spera G and **Gnessi L** Severe oligozoospermia in a boy with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. **Fertility and Sterility**, 95: 1120 e15-17, 2011 (4.167)
56. Ulisse S, Baldini E, Sorrenti S, Barollo S, **Gnessi L**, Catania A, Pellizzo MR, Nardi F, Mian C, De Antoni E, D'Armiento M, Frati L. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. **J Clin Endocrinol Metab.** 2011 Feb;96(2):504-8. (6.495)
57. Mariani S, Abruzzese E, Basciani S, Fiore D, Persichetti A, Watanabe M, Spera G, **Gnessi L**. Reversible hair depigmentation in a patient treated with imatinib. **Leuk Res.** 2011 Jun;35(6):e64-6. (2.923)
58. Funaro S, Galiuto L, Boccalini F, Cimino S, Canali E, Evangelio F, DeLuca L, Paraggio L, Mattatelli A, **Gnessi L**, Agati L. Determinants of microvascular damage recovery after acute myocardial infarction: results from the acute myocardial infarction contrast imaging (AMICI) multi-centre study. **Eur J Echocardiogr.** 2011 Apr;12(4):306-12. (2.117)
59. Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, **Gnessi L**, Griffin RJ, Minetti M, Malorni W. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. **International Journal of Cancer** 2012 15;131(4):E337-47. doi: 10.1002/ijc.26420 (4.926)
60. Mariani S, Fiore D, Barbaro G, Basciani S, Saponara M, D'Arcangelo E, Ulisse S, Moretti C, Fabbri A, **Gnessi L**. Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. **Int J Cardiol** 2013 Sep 1;167(5):2244-9. doi: 10.1016/j.ijcard.2012.06.011. Epub 2012 Jun 20 (7.08),
61. Basciani S, Watanabe M, Mariani S, Passeri M, Persichetti A, Fiore D, Scotto d'Abusco A, Caprio M, Lenzi A, Fabbri A and **Gnessi L**. Hypogonadism in a patient with two novel mutations of the luteinizing hormone beta-subunit gene expressed in a compound heterozygous form. **J Clin Endocrinol Metab.** 2012; 97(9), 3031-3038 (6.495)

62. *Ulissee S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, **Gnessi L**, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.* In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Clin Endocrinol 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x (3.323)
63. *Lubrano C, Saponara M, Barbaro G, Specchia P, Addessi E, Costantini D, Tenuta M, Di Lorenzo G, Genovesi G, Donini LM, Lenzi A, **Gnessi L**.* Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome.
PLoS One 2012;7(10):e47059 (4.092)
64. *Giona F, Mariani S, **Gnessi L**, Moleti ML, Rea M, De Vellis A, Marzella D, Testi AM, Foà R.* Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Haematologica 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14. (6.424)
65. *Baldini E, Sorrenti S, D'Armiento E, Guaitoli E, Morrone S, D'Andrea V, **Gnessi L**, Moretti C, Antonelli A, Catania A, De Antoni E, Ulisse S.* Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
La Clinica Terapeutica 2012;163(5):e307-13. (0.266)
66. *Mariani S, Fiore D, Varone L, Basciani S, Persichetti A, Watanabe M, Saponara M, Spera G, Moretti C, **Gnessi L**.* Obstructive sleep apnea and bone mineral density in obese patients.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012;5:395-401.
<http://dx.doi.org/10.2147/DMSO.S37761>
67. *Di Giacinto P, Chioma L, Vancieri G, Guccione L, Cicerone E, Ulisse S, Mariani S, Autore C, Fabbri A, **Gnessi L** and Moretti C.* Virilizing Leydig-Sertoli cell ovarian tumor associated with endometrioid carcinoma of the endometrium in a postmenopausal patient: case report and general considerations.
Clinical Medicine Insights: Case Reports 2012;5:149-53. doi: 10.4137/CCRep.S10555. Epub 2012 Oct 30.
68. *Mariani S, Musumeci B, Basciani S, Fiore D, Francia P, Persichetti A, Volpe M, Autore C, Moretti C, Ulisse S, **Gnessi L**.* Lack of influence of the androgen receptor gene CAG-repeat polymorphism on clinical and electrocardiographic manifestations of the Brugada syndrome in man.
Clinical Medicine Insights: Cardiology 2012;6:145-52. doi: 10.4137/CMC.S10553. Epub 2012 Oct 31.
69. *Baldini E, Sorrenti S, D'Armiento E, Prinzi N, Guaitoli E, **Gnessi L**, Moretti C, Bianchini M, Alessandrini S, Catania A, De Antoni E, Ulisse S.* Aurora kinases: new molecular targets in thyroid cancer therapy.
La Clinica Terapeutica 2012 Nov;163(6):e457-62 (0.266)
70. *Lubrano C, Genovesi G, Specchia P, Costantini D, Mariani S, Petrangeli E, Lenzi A, **Gnessi L**.* Obesity, metabolic syndrome and type 2 diabetes: environmental diseases.
Oxidative Medicine and Cellular Longevity 2013;2013:640673. doi: 10.1155/2013/640673. Epub 2013 Mar 18 (2.841)
71. *Baldini E, Sorrenti S, Di Gioia C, De Vito C, Antonelli A, **Gnessi L**, Carbotta G, Miccoli P, De Antoni E, Ulisse S.* Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?
BMC Clin Pathol 2013 Feb 19;13:7. doi: 10.1186/1472-6890-13-7 (3.333)
72. *Persichetti A, Sciuto R, Rea S, Basciani S, Lubrano C, Mariani S, Ulisse S, Nofroni I, Maini CL, **Gnessi L**.* Prevalence, Mass, and Glucose-Uptake Activity of ¹⁸F-FDG-Detected Brown Adipose Tissue in Humans Living in a Temperate Zone of Italy.
PLOS One. 2013 May 8;8(5):e63391. doi: 10.1371/journal.pone.0063391. Print 2013 (4.092)
73. *Mariani S, Basciani S, Giona F, Lubrano C, Ulisse S, **Gnessi L**.* Leptin modification in chronic myeloid leukemia patients treated with imatinib: an emerging effect of targeted therapy.
Leukemia Research Reports 2013 Nov 27;6:177-82. doi: 10.4137/CCRep.S12834. eCollection 2013. (2.19)
74. *Baldini E, Sorrenti S, Di Gioia C, De Vito C, Antonelli A, **Gnessi L**, Carbotta G, Miccoli P, De Antoni E, Ulisse S.* Effects of ultraviolet radiation on FRTL-5 cell growth and thyroid specific gene expression.
Astrobiology (2013 Jun;13(6):536-42. doi: 10.1089/ast.2013.0972. Epub 2013 May 22) (2.150)
75. *Mammi C, Caprio M, **Gnessi L**, Fabbri A.* Bisphosphonates and adipogenesis: evidence for alendronate inhibition of adipocyte differentiation in 3T3L1 preadipocytes through a vitamin d receptor mediated effect.
Natural Science 2013, Vol. 5 Issue 8, p955 ISSN 2150-4091
76. *Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, **Gnessi L**, Catania A, Moretti C, Mocini R, Carbotta G, Morrone S, Persechino S, Redler A, De Antoni E, D'Armiento M, Ulisse S.* The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Journal of Biological Regulators and Homeostatic Agents 2013; 27(3): 705-15 (5.183)
77. *Moretti C, Lupoi D, Spasaro F, Chioma L, Di Giacinto P, Colicchia M, Frajoli M, Mocini R, Ulisse S, Antonelli M, Giangaspero F, **Gnessi L**.* Sella turcica atypical teratoid/rhabdoid tumor complicated with lung metastasis in an adult female.
Clinical Medicine Insights: Case Reports 2013 Nov 27;6:177-82. doi: 10.4137/CCRep.S12834. eCollection 2013.
78. *Donini LM, Cuzzolaro M, **Gnessi L**, Lubrano C, Migliaccio S, Aversa A, Pinto A, Lenzi A.* Obesity treatment: results after 4 years of a Nutritional and Psycho-Physical Rehabilitation Program in an outpatient setting.
Eat Weight Disord. 2014 Jun;19(2):249-60. doi: 10.1007/s40519-014-0107-6. Epub 2014 Mar 1. (0.680)

79. Basciani S, Costantini D, Contini S, Persichetti A, Watanabe M, Mariani S, Lubrano C, Spera G, Lenzi A, **Gnessi L**. Safety and efficacy of a multiphase dietetic protocol with meal replacements including a step with very low calorie diet. **Endocrine**. 2014 Jul 26. [Epub ahead of print] (3.527)
80. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, **Gnessi L**, Morrone S, Moretti C, Bononi M, Arlot-Bonnemains Y, D'Armiento M, Ullisse S. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. **Endocr Relat Cancer**. 2014 Jul 29. pii: ERC-14-0299. [Epub ahead of print] (4.907)
81. Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C, Salvatori L, Lenzi A, **Gnessi L**. Plasma SIRT1 inversely associates with non-alcoholic fatty liver disease in obese patients. **Endocrine**. 2014 DOI 10.1007/s12020-014-0465-x (3.527)
82. Lubrano C, Tenuta M, Costantini D, Specchia P, Barbaro G, Basciani S, Mariani S, Pontecorvi A, Lenzi A, **Gnessi L**. Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study. **Endocrine**, DOI: 10.1007/s12020-015-0530-0 (3.527)
83. Persichetti A, Pallotti F, Bernabei A, Baldelli R, Rossi B, Fabi A, Corsello SM, **Gnessi L**, Biagini R, Torino F, Appetecchia M. Quality of life in breast cancer: a secret passage through skeletal muscle and bone. **Rev in Oncology** 2014; 2(1): 19-26
84. Poggiogalle E, Lubrano C, Mariani S, **Gnessi L**, Lenzi A, Donini LM. Fatty liver associates with growth hormone/insulin-like growth factor 1 profile, insulin sensitivity and sarcopenic obesity phenotype. **Int J Obesity**, 2015 Aug 21. doi: 10.1038/ijo.2015.163. [Epub ahead of print] (5.386)
85. Mariani S, Fiore D, Persichetti A, Basciani S, Lubrano C, Poggiogalle E, Genco A, Donini LM, **Gnessi L**. Circulating SIRT1 increases after intragastric balloon fat loss in obese patients. **Obesity Surgery**, accepted (3.739)
86. **Gnessi L**, Bacarea V, Marusteri M, Pique N. Gelatin-xyloglucan, a medical device for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial **BMC Gastroenterology**, 2015 Oct 30;15(1):153. doi: 10.1186/s12876-015-0386-z (2.11)
87. Ponterio E, Cangemi R, Mariani S, Casella G, De Cesare A, Trovato GM, Garozzo A, **Gnessi L**. Presence of Adenovirus 36 DNA in human Adipose Tissue. **Int J Obesity**, 2015 Aug 21. doi: 10.1038/ijo.2015.163. [Epub ahead of print] (5.386)
88. Poggiogalle E, Lubrano C, Sergi G, Coin A, **Gnessi L**, Mariani L, Lenzi A, Donini LM. Sarcopenic obesity and metabolic syndrome in adult Caucasian subjects: a focus on insulin resistance, inflammation and protein metabolism. **Journal of Nutrition, Health and Aging**, accepted (2.996)
89. Romagnoli E, Lubrano C, Carnevale V, Costantini D, Nieddu L, Morano S, Migliaccio S, **Gnessi L**, Lenzi A. Obesity and Insulin Resistance Influence Bone Microarchitecture in Men as Evaluated by the Trabecular Bone Score (TBS) **Endocrine**, accepted (3.527)
90. Lubrano C, Valacchi G, Specchia P, **Gnessi L**, Rubanenko EP, Shuginina EA, Trukhanov A, Korkina L and De Luca C Integrated haematological profiles of redox status, lipid, and inflammatory protein biomarkers in benign obesity and unhealthy obesity with metabolic syndrome **Oxidative Medicine and Cellular Longevity**, 2015;2015:490613. doi: 10.1155/2015/490613. Epub 2015 May 18 (3.363)
91. Ponterio E, **Gnessi L**. Adenovirus 36 and obesity: an overview. **Viruses**, 2015, 7, 3719-3740; doi:10.3390/v7072787 (3.279)
92. Schutte AE, Conti E, Mels C, Smith W, Kruger R, Botha S, **Gnessi L**, Volpe M, Huisman HW Attenuated IGF-1 predicts hypertension, all-cause and cardiovascular mortality in a black population: a 5-year prospective study. **European Journal of Preventive Cardiology**, 2016, Vol. 23(16) 1690-1699 (3.361)
93. Lubrano C, Masieri S, Costantini D, Francomano D, Watanabe M, S Mariani S, Basciani S, Donini LM, Lenzi A, **Gnessi L** Nickel sensitivity in Italian overweight-obese patients. **European Journal of Public Health**, Vol. 25, Supplement 3, 370, 2015 (2.591)
94. Poggiogalle E, Lubrano C, Mariani S, **Gnessi L**, Lenzi A, Donini LM. Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. **PLOS One**, 2016 Jan 7;11(1):e0145811. doi: 10.1371/journal.pone.0145811 (4.092)
95. Mariani S, Costantini D, Lubrano C, Basciani S, Caldaroni C, Barbaro G, Poggiogalle E, Donini LM, Lenzi A, **Gnessi L**. Circulating SIRT1 inversely correlates with epicardial fat thickness in patients with obesity. **Nutrition, Metabolism & Cardiovascular Diseases**. Accepted (3.323)
96. Sanguigni V, Manco M, Sorge R, **Gnessi L**, Francomano D. Natural antioxidant ice cream acutely reduces oxidative stress and improves vascular function and physical performance in healthy subjects. **Nutrition**, 2016 Jul 26. pii: S0899-9007(16)30128-9. doi: 10.1016/j.nut.2016.07.008 (2.839)
97. Donini LM, Merola G, Poggiogalle E, Lubrano C, **Gnessi L**, Mariani S, Migliaccio S, Lenzi A. Disability, Physical Inactivity, and Impaired Health-Related Quality of Life Are Not Different in Metabolically Healthy vs. Unhealthy Obese Subjects. **Nutrients** 2016, 8, 759; doi:10.3390/nu8120759 (3.759)
98. Astrup A, Kristensen M, **Gnessi L**, Watanabe M, Svacina S, Matoulek M, Hlubik P, Stritecka H, Contaldo F, Pasanisi F, Zohar Y, Ron ES, Urban LE, Sannino A, Demitri C, Saponaro C, Heshmati HM. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of a Novel Oral Non-Systemic Hydrogel on Body Weight in

Overweight and Obese Subjects (FLOW Study).

New Engl J Med, submitted (**59.558**)

99. *Moretti M, Lanzolla G, Preziosi N, Grammatico P, Brancati F, De Smaele E, **Gnessi L**, Maroder M and Moretti C.* A novel androgen receptor gene frameshift mutation involving NF- κ B signaling repression in a 46,XY female with CAIS and testicular hamartoma.

J Clin Endocrinol Metab, submitted (**6.209**)

100. *Scarselli F, Mariani S, Lubrano C, Basciani S, Franco G, Farcomeni A, Greco E, **Gnessi L**.* Testicular histopathology, semen analysis and FSH plasma concentration predict sperm retrieval rate by conventional testicular sperm extraction (TESE).

European Urology, submitted (**14.976**)

Allegato 2

Clinical studies		
2016	Comparative open study of very low calories diets in obese patients. New Penta srl. Via Piave, 10 – 12040 Castelletto Stura (CN). Prot. N. Penta 0915	Principal Investigator
2015	G-04 - GLOW – “Studio randomizzato in doppio cieco, controllato con placebo, a gruppi paralleli per la valutazione dell’effetto di Gelesis100 sul peso corporeo in soggetti in sovrappeso ed obesi con e senza diabete di tipo 2” Gelesis Srl, Napoli, Galleria Umberto I, 8-80132	Principal Investigator
2013	“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Attiva on Body Weight in Overweight and Obese Subjects” Gelesis Srl, Napoli, Galleria Umberto I, 8-80132	Principal Investigator
2013	Studio aperto per la valutazione della sicurezza, dell’efficacia e della compliance del programma dietetico multifasico PENTADIET a base di pasti sostitutivi. New Penta srl. Via Piave, 10 – 12040 Castelletto Stura (CN)	Principal investigator
2011	Phase III T-emerge study in patients with diabetes with taspoglutide, a once weekly glucagon-like peptide-1 (GLP-1) analogue. F. Hoffmann-La Roche Ltd	Principal investigator
2005	A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the efficacy and safety of tadalafil (2.5 and 5 mg) administered once daily in men with diabetes mellitus and erectile dysfunction. H6D-MC-LVFZ Eli Lilly Italia S.p.A., Via A. Gramsci, 731-733, 50019 Sesto Fiorentino (FI) Italia	Principal investigator
1998	Phase III trial Orlistat in the treatment of obesity F. Hoffmann-La Roche Ltd	Principal investigator